NCT05185219

Brief Summary

Menopausal women often complain that it is difficult to fall asleep and easy to wake up at night and early in the morning and it is in the middle of night difficult to fall asleep again. If the above symptoms persist for at least three months and occur at least three times a week, plus the impact on daytime work and rest, and meet the International Classification of Sleep Disorders (ICSD-3) )'S s "Insomnia" diagnostic criteria. According to statistics, 30% to 60% of women face sleep disorders during menopause.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2021

Completed
11 days until next milestone

Study Start

First participant enrolled

December 14, 2021

Completed
28 days until next milestone

First Posted

Study publicly available on registry

January 11, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2025

Completed
Last Updated

April 8, 2024

Status Verified

April 1, 2024

Enrollment Period

3.1 years

First QC Date

December 3, 2021

Last Update Submit

April 5, 2024

Conditions

Keywords

menopauseinsomniavalerian

Outcome Measures

Primary Outcomes (1)

  • Sleep quallity

    Sleep quality will be evaluated by Pittsburgh Sleep Index (PSQI). The sum of the scores on PSQI ranges from 0 to 21, and higher scores mean a worse outcome.

    30 days

Secondary Outcomes (1)

  • Traditional Chinese medicine (TCM) constitution

    30 days

Study Arms (2)

Valerian

EXPERIMENTAL

generic name: XIE CAO CONC dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days

Drug: Valerian

Control

PLACEBO COMPARATOR

generic name: placebo (Caramel Colors dyed starch) dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days

Drug: Valerian

Interventions

A natural plant

ControlValerian

Eligibility Criteria

Age45 Years - 60 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale-specific condition
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • 〜60 years old, and is menopaused for at least 1 year。
  • meet the criteria of ICSD-3 for insomnia
  • PSQI \> 5

You may not qualify if:

  • psychiatry disease
  • Heart, brain, liver diseases
  • Insomnia is caused by diseases.
  • Steroid used within 6 months
  • pregnant or breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University

Taichung, Taiwan

RECRUITING

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

Valeriana extract

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

December 3, 2021

First Posted

January 11, 2022

Study Start

December 14, 2021

Primary Completion

January 20, 2025

Study Completion

January 20, 2025

Last Updated

April 8, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations